Trimetazidine is NOT recommended for acute coronary syndrome (ACS) based on current guidelines
The most recent 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines for ACS management do not include trimetazidine in their treatment recommendations. 12 The guideline-directed medical therapy for ACS focuses on dual antiplatelet therapy (aspirin plus P2Y12 inhibitor like ticagrelor or prasugrel), anticoagulation, and early revascularization strategies—trimetazidine is conspicuously absent from these evidence-based recommendations.
Why Trimetazidine is Not Standard ACS Therapy
The 2025 ACS guidelines emphasize:
- Dual antiplatelet therapy (aspirin + ticagrelor/prasugrel preferred over clopidogrel) for at least 12 months 12
- Parenteral anticoagulation (UFH, enoxaparin, bivalirudin, or fondaparinux) until revascularization 1
- Early invasive strategy with PCI or CABG as appropriate 1
- Complete revascularization in STEMI and NSTE-ACS 1
Trimetazidine is not mentioned in any of these core treatment pathways.
Important Context About Trimetazidine
While trimetazidine is approved in some countries as add-on therapy for stable angina (not ACS) when first-line agents are inadequate 34, the evidence for ACS is limited:
- Small studies suggest potential benefits in reducing myocardial damage during PCI 56 and improving heart rate variability 7
- However, these are small, underpowered studies that cannot establish effects on hard clinical outcomes like mortality 83
- A 2019 review noted "only a few studies have assessed its effects in patients with acute ischemic conditions" 9
Critical Pitfall to Avoid
Do not confuse stable angina with ACS. The FDA labeling you referenced 101010 is actually for triamterene/hydrochlorothiazide (a diuretic combination), not trimetazidine—this appears to be a data error. Trimetazidine's approved indication is for chronic stable angina as second-line therapy, not acute coronary syndromes 34.
The Bottom Line
For ACS angina, stick to guideline-directed therapy: aspirin, potent P2Y12 inhibitor, anticoagulation, beta-blockers, statins, and revascularization. Trimetazidine lacks sufficient evidence for ACS and is not part of standard care. If a patient has persistent angina after ACS treatment and stabilization, trimetazidine might be considered later as add-on therapy for chronic stable angina, but this is a different clinical scenario entirely.